MCMinia Campos‐Domínguez

Minia Campos‐Domínguez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Minia Campos‐Domínguez has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Peculiar Phenotype of Linear Prepubertal Hidradenitis Suppurativa Associated With Trisomy 13: Report of Two Clinical Cases

    by Luis Ángel Zamarro Díaz, Paloma García Piqueras, Marina de la Puente Alonso, Minia Campos Domínguez

    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that typically affects intertriginous areas and is rarely associated with chromosomal abnormalities. This report describes two pediatric cases of HS‐like lesions overlying phylloid pigmentary mosaicism, both associated with mosaic trisomy 13. The first case involves a 5‐year‐old girl with developmental anomalies and comedonal lesions localized to areas of pigmentary mosaicism, confirmed by skin biopsy showing 30% aneuploid cells with full trisomy 13. The second case is a 15‐month‐old girl who developed follicular lesions years later overlying a hypopigmented mosaic patch; genetic analysis of skin tissue revealed 50% aneuploid cells with partial trisomy 13. These cases support an emerging link between mosaic trisomy 13 and follicular occlusion disorders, including HS. The involvement of chromosome 13 genes, such as GJB2 (connexin 26), may play a role in the pathogenesis.

  • Open Access

    Happle-Tinschert syndrome in an infant: clinical, radiologic and genetic correlation

    by Belén Rodríguez-Sanchez, Francisco Javier Narbona-Cárceles, Jorge Martín-Nieto-González, Marina de la Puente-Alonso, Luis Zamarro-Díaz, Luis Jiménez-Briones, Julia Suárez-González, Francisco Arias-Lotto, Minia Campos-Domínguez

    Happle-Tinschert syndrome (HTS) is a rare mosaic disorder characterized by segmental basaloid follicular hamartomas (BFH) and variable multisystem involvement, including skeletal, dental, and occasional neurologic abnormalities. 1-5) Although cutaneous findings often prompt initial evaluation, the condition is clinically relevant to pediatricians because growth-plate abnormalities can evolve silently and cause progressive deformities throughout childhood. 3,4) Early recognition, targeted genetic testing of affected tissue, and multidiscipli nary follow-up are essential for adequate care. HTS belongs to the mosaic hedgehog-pathway spectrum, which also includes Curry-Jones syndrome and segmental basal cell nevus syndrome. These entities arise from

  • Post‐Hematopoietic Stem Cell Transplantation Eczematous Dermatitis Spectrum Successfully Treated With Dupilumab: A Case Series and Review of the Literature

    by Belén Rodríguez‐Sánchez, Minia Campos‐Domínguez, Antonio del Alcalá‐Ramírez del Puerto, José Bernabeu‐Wittel, María Teresa Monserrat‐García, Francisco Arias‐Lotto, Veronica Parra‐Blanco, Cristina Beléndez‐Bieler, Marina García‐Morín, Eduardo Bardón‐Cancho, et al.

    Background: Hematopoietic stem cell transplantation (HSCT) is associated with several dermatological adverse events, including the de novo onset of pruritus and eczema. Some authors consider this a variant of graft‐versus‐host disease (GvHD) and refer to it as eczematous or atopic dermatitis (AD)‐like GvHD, while others categorize it separately as eczematous or AD‐like dermatitis. This study aimed to report a pediatric case series and review previously published cases treated with dupilumab. Methods: Retrospective multicenter study including patients aged 0–18 treated with dupilumab for new eczematous lesions following HSCT up to 2024 in three tertiary hospitals in Spain. A literature review in PubMed identified all reported pediatric and adult cases. Results: A total of 24 cases were identified: 9 from our centers and 15 from the literature. Median onset was 3 months post‐HSCT. All patients presented with pruritus and eczema. 47% showed flexural involvement. Histology revealed eczematous features in 73%, mixed GvHD/eczema in 20%, and pure GvHD in 7%. 38% were classified as post‐HSCT eczema, and 63% as eczematous or AD‐like GvHD. All were refractory to topical corticoids and different systemic immunosuppressants. Dupilumab led to complete or near‐complete resolution in 96% of cases. No serious adverse events were reported. Conclusion: Dupilumab appears to be effective and safe for eczematous lesions occurring after HSCT, regardless of whether the histopathological characteristics align with eczema or GvHD. This supports a shared spectrum between eczematous dermatitis and GvHD, and the use of a neutral diagnostic term. Further research is needed to clarify its pathogenesis.


  • Vulvar erosions in a young girl

    by Ana Taibo, Isabel Colmenero, Minia Campos, Antonio Torrelo


  • Open Access

    Kaposiform hemangioendothelioma and tufted angioma: two entities of the same clinicopathological spectrum

    by Lula María Nieto-Benito, Jorge Huerta-Aragonés, Verónica Parra-Blanco, Minia Campos-Domínguez


  • Inter‐ and intra‐observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain

    by María Colmenero, Javier del Boz, José Bernabeu Wittel, Esther Roé, Marta Feito‐Rodríguez, María Asunción Vicente‐Villa, Ana Martín‐Santiago, Sara Isabel Palencia Pérez, Antoni Azon, Marta Valdivielso‐Ramos, et al.

    Background: Guidelines and expert recommendations on infantile hemangiomas (IH) are aimed at increasing homogeneity in clinical decisions based on the risk of sequelae.Objective: The objective was to analyze the inter‐ and intra‐observer agreement among pediatric dermatologists in the choice of treatment for IH.Methods: We performed a cross‐sectional inter‐rater and intra‐rater agreement study within the Spanish infantile hemangioma registry. Twenty‐seven pediatric dermatologists were invited to participate in a survey with 50 clinical vignettes randomly selected within the registry. Each vignette contained a picture of an infantile hemangioma with a clinical description. Raters chose therapy among observation, topical timolol, or oral propranolol. The same survey reordered was completed 1 month later to assess intra‐rater agreement. Vignettes were stratified into hemangioma risk categories following the Spanish consensus on IH. The agreement was measured using kappa statistics appropriate for the type of data (Gwet's AC1 coefficient and Gwet's paired t test).Results: Twenty‐four dermatologists completed the survey. Vignettes represented 7.8% of the Spanish hemangioma registry. The inter‐rater agreement on the treatment decision was fair (AC1 = 0.39, 95% confidence interval [CI]: 0.30–0.47). When stratified by risk category, good agreement was reached for high‐risk hemangiomas (AC1 = 0.77, 95% CI: 0.51–1.00), whereas for intermediate‐ and low‐risk categories, the agreement was only fair (AC1 0.31, 95% CI: 0.16–0.46 and AC1 = 0.38, 95% CI: 0.27–0.48, respectively). Propranolol was the main option for high‐risk hemangiomas (86.4%), timolol for intermediate‐risk (36.8%), and observation for low‐risk ones (55.9%). The intra‐rater agreement was good. The inter‐rater agreement between pediatric dermatologists on the treatment of IH is only fair. Variability was most significant with intermediate‐ and low‐risk hemangiomas.


  • Open Access

    Juvenile Xanthogranuloma as Differential Diagnosis of a Vulvar Mass: A Case Report

    by Isabel Bada Bosch, Agustín del Cañizo, Minia Campos-Domínguez, Javier Ordoñez, María Dolores Blanco Verdú, María Fanjul, Laura Pérez-Egido, Juan Carlos de Agustín

    Vulvar masses in children are an unusual finding but their differential diagnosis is extensive. In case of solid masses, rhabdomyosarcoma (RMS) must always be considered due to the fact that it is the most common tumor in external genitals during childhood. However, RMS has a radiological appearance very similar to juvenile xanthogranuloma (JXG). We present a 16-month-old girl with a 2 cm solid mass on her left labia majora, with four overlying cutaneous papules. After imaging tests, an excisional biopsy was programmed due to high malignancy suspicion. Histopathology of the mass and one of the papules was diagnostic for JXG. After a 12-month follow-up, the patient shows no signs of relapse or complication. Deep JXG is an uncommon entity in childhood and exceptional in the genital area. Therefore, it must be included in the differential diagnosis of a solid vulvar mass, especially if accompanying yellowish xanthomatous cutaneous lesions are present.


  • Open Access

    Fibromatosis digital infantil: primum non nocere

    by E. Rodríguez-Lomba, B. Lozano-Masdemont, M. Campos-Domínguez


  • Ectodermal dysplasia with congenital adermatoglyphia (Basan syndrome): Report of two cases presenting with extensive congenital milia

    by Lula María Nieto‐Benito, Irene Molina‐López, Marta Feito‐Rodríguez, Víctor Martínez‐González, Ricardo Suárez‐Fernández, Minia Campos‐Dominguez

    Basan syndrome is a rare autosomal dominant genodermatosis, characterized by rapidly healing congenital acral bullae, congenital milia and adermatoglyphia (lack of finger and toeprints). This type of ectodermal dysplasia has been infrequently reported in the literature. A pathogenic mutation in the SMARCAD1 gene has been demonstrated to cause this rare disorder.


  • Successful treatment of giant lymphatic malformation with symptomatic cutaneous vesicles by surgical excision and coverage with Integra®

    by Beatriz Berenguer, Concepción Lorca-García, Maria San-Basilio, Minia Campos, Angel Lancharro, Carolina Agra